[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Paletta Guedes et al., 2022 - Google Patents

Standalone Implantation of 2–3 trabecular micro-bypass stents (iStent inject±iStent) as an alternative to trabeculectomy for moderate-to-severe glaucoma

Paletta Guedes et al., 2022

View HTML @Full View
Document ID
4429674807145278836
Author
Paletta Guedes R
Gravina D
Paletta Guedes V
Chaoubah A
Publication year
Publication venue
Ophthalmology and Therapy

External Links

Snippet

Introduction This retrospective consecutive study compared standalone implantation of multiple (2–3) trabecular micro-bypass stents (iStent inject±iStent)(Multi-Stent group) vs trabeculectomy+ mitomycin C (Trab group) in moderate to severe open-angle glaucoma …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Myers et al. Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma: 4-year outcomes
Misra et al. 23-gauge sutureless vitrectomy and 20-gauge vitrectomy: a case series comparison
Hengerer et al. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma
Hengerer et al. Second-generation trabecular micro-bypass stents as standalone treatment for glaucoma: a 36-month prospective study
Clement et al. One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study
Ferguson et al. Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract
Hengerer et al. iStent inject trabecular micro-bypass with or without cataract surgery yields sustained 5-year glaucoma control
Berdahl et al. Implantation of two second‐generation trabecular micro‐bypass stents and topical travoprost in open‐angle glaucoma not controlled on two preoperative medications: 18‐month follow‐up
Paletta Guedes et al. Standalone Implantation of 2–3 trabecular micro-bypass stents (iStent inject±iStent) as an alternative to trabeculectomy for moderate-to-severe glaucoma
Sarkisian et al. 360 ab-interno trabeculotomy in refractory primary open-angle glaucoma
Tanner et al. One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis
Salimi et al. Second-generation trabecular micro-bypass (iStent inject) with cataract surgery in eyes with normal-tension glaucoma: one-year outcomes of a multi-centre study
Holmes et al. Comparative study of 2‐year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Clement et al. Two-year multicenter outcomes of iStent inject trabecular micro-bypass stents combined with phacoemulsification in various types of glaucoma and ocular hypertension
Sheybani et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months
Ferguson et al. iStent inject trabecular microbypass stent implantation with cataract extraction in open-angle glaucoma: early clinical experience
Sharpe et al. Comparison of ab interno XEN gelatin stent vs trabeculectomy with mitomycin C: a retrospective study
Vastardis et al. Preliminary results of preserflo microshunt versus preserflo microshunt and ologen implantation
Paletta Guedes et al. Two-year comparative outcomes of first-and second-generation trabecular micro-bypass stents with cataract surgery
Kostanyan et al. Longer-term Baerveldt to Trabectome glaucoma surgery comparison using propensity score matching
Hong et al. Safety and efficacy outcomes of the Xen45 Gel Stent use for refractory glaucoma: a surgery series from surgeon trainees at a tertiary teaching hospital
Chang et al. Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma
Hengerer et al. 7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage
Singh et al. Treatment success across different levels of preoperative disease burden: stratified two-year outcomes from the pivotal trial of iStent inject® trabecular micro-bypass in primary open-angle glaucoma and cataract
Inatani et al. iStent trabecular micro-bypass stent implantation combined with phacoemulsification for open-angle glaucoma: A 2-year post-marketing surveillance study in Japan